+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines



Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines



Journal of Neurosurgery. Spine 21(3): 386-393



Chordoma cells can generate solid-like tumors in xenograft models that express some molecular characteristics of the parent tumor, including positivity for brachyury and cytokeratins. However, there is a dearth of molecular markers that relate to chordoma tumor growth, as well as the cell lines needed to advance treatment. The objective in this study was to isolate a novel primary chordoma cell source and analyze the characteristics of tumor growth in a mouse xenograft model for comparison with the established U-CH1 and U-CH2b cell lines. Primary cells from a sacral chordoma, called "DVC-4," were cultured alongside U-CH1 and U-CH2b cells for more than 20 passages and characterized for expression of CD24 and brachyury. While brachyury is believed essential for driving tumor formation, CD24 is associated with healthy nucleus pulposus cells. Each cell type was subcutaneously implanted in NOD/SCID/IL2Rγ(null) mice. The percentage of solid tumors formed, time to maximum tumor size, and immunostaining scores for CD24 and brachyury (intensity scores of 0-3, heterogeneity scores of 0-1) were reported and evaluated to test differences across groups. The DVC-4 cells retained chordoma-like morphology in culture and exhibited CD24 and brachyury expression profiles in vitro that were similar to those for U-CH1 and U-CH2b. Both U-CH1 and DVC-4 cells grew tumors at rates that were faster than those for U-CH2b cells. Gross tumor developed at nearly every site (95%) injected with U-CH1 and at most sites (75%) injected with DVC-4. In contrast, U-CH2b cells produced grossly visible tumors in less than 50% of injected sites. Brachyury staining was similar among tumors derived from all 3 cell types and was intensely positive (scores of 2-3) in a majority of tissue sections. In contrast, differences in the pattern and intensity of staining for CD24 were noted among the 3 types of cell-derived tumors (p < 0.05, chi-square test), with evidence of intense and uniform staining in a majority of U-CH1 tumor sections (score of 3) and more than half of the DVC-4 tumor sections (scores of 2-3). In contrast, a majority of sections from U-CH2b cells stained modestly for CD24 (scores of 1-2) with a predominantly heterogeneous staining pattern. This is the first report on xenografts generated from U-CH2b cells in which a low tumorigenicity was discovered despite evidence of chordoma-like characteristics in vitro. For tumors derived from a primary chordoma cell and U-CH1 cell line, similarly intense staining for CD24 was observed, which may correspond to their similar potential to grow tumors. In contrast, U-CH2b tumors stained less intensely for CD24. These results emphasize that many markers, including CD24, may be useful in distinguishing among chordoma cell types and their tumorigenicity in vivo.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054435981

Download citation: RISBibTeXText

PMID: 24905390

DOI: 10.3171/2014.4.spine13262


Related references

Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma. Journal of Neurosurgery. Spine 25(5): 626-635, 2016

Molecular characterization of putative chordoma cell lines. Sarcoma 2010: 630129, 2010

Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319. Journal of Experimental and Clinical Cancer Research 29: 158, 2010

Sarcomatoid chordoma: chordoma with a massive malignant spindle-cell component. Skeletal Radiology 29(12): 721-725, 2000

Three cases of intracranial chordoma. Typical chordoma and chondroid chordoma. No Shinkei Geka. Neurological Surgery 12(5): 591-598, 1984

Incipient chordoma: a report of two cases of early-stage chordoma arising from benign notochordal cell tumors. Modern Pathology 18(7): 1005-1010, 2005

Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. Journal of Neurosurgery 120(2): 331-336, 2014

Secondary pulmonary conventional chordoma arising from primary sarcomatoid chordoma of the sacrum: A case report. Oncology Letters 8(1): 208-210, 2014

Axial chordoma and parachordoma (soft tissue chordoma): two of a kind: report of two cases with primary diagnosis on fine-needle cytology samples. Diagnostic Cytopathology 39(7): 475-481, 2011

Characterization and analysis of human chordoma cell lines. Spine 35(13): 1257-1264, 2010

Cytogenetics and molecular genetic characterization of the first human chordoma cell line U-CH1. Pathology Research & Practice 196(6): 352, 2000

A comparative ultrastructural study of chondrosarcoma, chordoid sarcoma, chordoma and chordoma periphericum. Pathology Research and Practice 179(4-5): 546-559, 1985

Chordoma cutis, an unusual clinical presentation of a rare neoplasm: Chordoma. Annales de Pathologie 38(2): 126-130, 2018

Malignant chordoma of the cranial base; clivus and so-called hypophyseal chordoma. Zentralblatt für Allgemeine Pathologie U. Pathologische Anatomie 98(9-11): 512-521, 1958

A vertebral extra dural chordoma at C5, possibly deriving from a clival chordoma. Surgical Neurology International 6: 94, 2015